Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.vrtx.com
Vertex Pharmaceuticals News Releases
Get the latest updates from Vertex Pharmaceuticals News Releases directly as they happen.
Follow now 59 followers
Latest posts
Last updated 5 days ago
Vertex Reports First Quarter 2025 Financial Results
5 days ago
— Total revenue of $2.77 billion , a 3% increase compared to...
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
13 days ago
- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years...
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
29 days ago
BOSTON --(BUSINESS WIRE)--Apr. 11, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced...
Vertex to Announce First Quarter 2025 Financial Results on May 5th
about 1 month ago
BOSTON --(BUSINESS WIRE)--Apr. 7, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report...
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis
about 1 month ago
-Approximately 4,000 people living with CF in the European Union are newly...
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
about 1 month ago
- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and...
Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
2 months ago
- Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older...
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
2 months ago
-If approved, approximately 4,000 people with cystic fibrosis in the European Union...
Vertex to Participate in Upcoming March Investor Conferences
3 months ago
BOSTON --(BUSINESS WIRE)--Feb. 18, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced...
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
3 months ago
— Full year product revenue of $11.02 billion , a 12% increase...
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
3 months ago
- Agreement means eligible sickle cell disease (SCD) patients in England now...
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
3 months ago
-- JOURNAVX is the first and only approved non-opioid oral pain signal...